Addex Therapeutics Reports Q2 Net Loss Amid Decreased Revenue
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Sep 30 2025
0mins
Source: NASDAQ.COM
Financial Performance: Addex Therapeutics reported a net loss of 1.84 million Swiss Francs in Q2, a significant decline from a profit of 12.88 million Francs in the same period last year, with total loss per share at 0.02 Francs.
Operational Developments: The company is focusing on mGlu5 NAMs for brain injury treatment and has entered an option agreement with Sinntaxis to access additional intellectual property, aiming to explore the clinical activity of dipraglurant.
Analyst Views on ADXN
About ADXN
Addex Therapeutics Ltd is a Switzerland-based clinical-stage pharmaceutical company. The Company focuses on development and commercialization of orally available small molecule drugs known as allosteric modulators for neurological disorders. The Company’s clinical programs pipeline include dipraglurant (mGlu5 NAM), which is Phase 2a placebo-controlled clinical trial for Parkinson's disease levodopa-induced dyskinesia (PD-LID), and is being prepared to enter registration trials for PD-LID, and ADX71149 (mGlu2 positive allosteric modulator or PAM), which is being developed in collaboration by its partner Janssen Pharmaceuticals, Inc to treat schizophrenia and anxious depression. It also is advancing several preclinical programs, including GABABPAM for pain, overactive bladder and other disorders, mGlu7 NAM for post-traumatic stress disorder, mGlu2 NAM for mild neurocognitive disorders, mGlu4 PAM for Parkinson’s disease and mGlu3 PAM for neurodegenerative disorders.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
